The paradox of scored tablets: A cost-saving risk

Pharmazie

Volumn 64, Issue 8, 2009, Pages 550-552

  De Spiegeleer, Bart ^a   Van Hoorebeke, L ^a   De Spiegeleer, A ^a   Castelein, P ^a   Van Bortel, L ^b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; COST BENEFIT ANALYSIS; HUMAN; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TABLET; COST CONTROL; DRUG INDUSTRY; DRUG LEGISLATION; ECONOMICS; HEALTH INSURANCE; PHARMACIST; RISK;

COST SAVINGS; DRUG INDUSTRY; INSURANCE, HEALTH; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; RISK; TABLETS;

EID: 70349767350     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9532     Document Type: Article

References (16)

1. Bachynsky J, Wiens C, Melnychuk K (2002) The practice of splitting tablets: cost and therapeutic aspects. Pharmacoeconomics 20: 339-345.
2. Barends DM, Groot DW, Frijlink HW, Rodenhuis N, van der Steen JC (2005) Development of an in vivo test procedure for the ease of breaking of scored tablets. Pharm Eur Sci Notes 1: 27-30.
3. CDER (Center for Drug Evaluation and Research ). "Scale-Up and Post-Approval Changes for Intermediate Release Products" (SUPAC-IR), Appendix A, November 1995.
4. De Spiegeleer B et al. (2005) Mass uniformity: influence of operational compression conditions on breakability of scored tablets as part of manufacturing robustness evaluation. J Food Drug Analysis 13: 22-29.
5. FDA, FDA-approved labeling for warfarin (Coumadin) NDA 9-218/5-105. Press release of the Food and Drug Administration, Rockville,MD, August 16, 2007. (http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html.)
6. Peck CC, Cross JT (2007) Getting the dose right: facts, a blueprint, and encouragements. Clin Pharmacol Ther 82: 12-14.
7. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 357: 2552-2561.
8. Quinzler R, Bertsche T, Szecsenyi J, Haefeli WE (2008) Teilung von Tabletten: Welchen Einfluss haben die Rabattverträge auf die Verordnungsqualita ̈t? Med Klinik 103: 569-574.
9. Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE (2006) The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 62: 1065-1073.
10. Quinzler R, Szecsenyi J, Haefeli W (2007) Tablet splitting: patients and physicians need better support. Eur J Clin Pharmacol 63: 1203-1204.
11. Rodenhuis N, De Smet P, Barends D (2004) The rationale of scored tablets as dosage form. Eur J Pharm Sci 21: 305-308.
12. Schwarz UI, Ritchie, MD, Bradford Y, Li C, Dudek SM, Frye-Anderson, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358: 999-1008.
13. Stafford S, Randell S (2002) The potential of pill splitting to achieve cost savings. The American Journal of Managed Care 8: 706-712.
14. van Santen E, Barends DM, Frijlink HW (2002) Breaking of scored tablets: a review. Eur J Pharm Biopharm 53: 139-45.
15. Van Vooren L, De Spiegeleer B, Thonissen T, Joye P, Van Durme J, Slegers G (2002) Statistical analysis of tablet breakability methods. J Pharm Pharmaceut Sci 5: 190-198.
16. Weissman E, Dellenbaugh C (2007) Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia. Psychiatric Services 58: 201-206.